ASX - By Stock
|
NEU |
Re:
Phase 2
|
|
hottod
|
25 |
12K |
28 |
06/11/23 |
06/11/23 |
ASX - By Stock
|
25
|
12K
|
28
|
|
ASX - By Stock
|
NEU |
Re:
Phase 2
|
|
hottod
|
25 |
12K |
53 |
06/11/23 |
06/11/23 |
ASX - By Stock
|
25
|
12K
|
53
|
|
ASX - By Stock
|
NEU |
Re:
Neuren Media and Analyst Coverage
|
|
hottod
|
1.3K |
703K |
75 |
06/11/23 |
06/11/23 |
ASX - By Stock
|
1.3K
|
703K
|
75
|
|
ASX - By Stock
|
PNV |
Re:
Ann: AGM - Chairman and CEO address to shareholders
|
|
hottod
|
70 |
28K |
27 |
06/11/23 |
06/11/23 |
ASX - By Stock
|
70
|
28K
|
27
|
|
ASX - By Stock
|
PNV |
Re:
Ann: AGM - Chairman and CEO address to shareholders
|
|
hottod
|
70 |
28K |
73 |
04/11/23 |
04/11/23 |
ASX - By Stock
|
70
|
28K
|
73
|
|
ASX - By Stock
|
PNV |
Re:
The Clinicians Speak
|
|
hottod
|
1.0K |
416K |
41 |
02/11/23 |
02/11/23 |
ASX - By Stock
|
1.0K
|
416K
|
41
|
|
ASX - By Stock
|
PNV |
Re:
The Clinicians Speak
|
|
hottod
|
1.0K |
416K |
43 |
02/11/23 |
02/11/23 |
ASX - By Stock
|
1.0K
|
416K
|
43
|
|
ASX - By Stock
|
PTX |
Re:
Ann: September 2023 Quarterly Update and Appendix 4C
|
|
hottod
|
26 |
8.3K |
25 |
01/11/23 |
01/11/23 |
ASX - By Stock
|
26
|
8.3K
|
25
|
|
ASX - By Stock
|
NEU |
Re:
Rare paediatric disease priority review
|
|
hottod
|
30 |
20K |
38 |
31/10/23 |
31/10/23 |
ASX - By Stock
|
30
|
20K
|
38
|
|
ASX - By Stock
|
NEU |
Re:
Share Price
|
|
hottod
|
11K |
5.4M |
28 |
26/10/23 |
26/10/23 |
ASX - By Stock
|
11K
|
5.4M
|
28
|
|
ASX - By Stock
|
NEU |
Re:
Phase 2
|
|
hottod
|
25 |
12K |
49 |
25/10/23 |
25/10/23 |
ASX - By Stock
|
25
|
12K
|
49
|
|
ASX - By Stock
|
NEU |
Re:
Phase 2
|
|
hottod
|
25 |
12K |
45 |
25/10/23 |
25/10/23 |
ASX - By Stock
|
25
|
12K
|
45
|
|
ASX - By Stock
|
NEU |
Re:
Phase 2
|
|
hottod
|
25 |
12K |
60 |
25/10/23 |
25/10/23 |
ASX - By Stock
|
25
|
12K
|
60
|
|
ASX - By Stock
|
NEU |
Re:
Phase 2
|
|
hottod
|
25 |
12K |
61 |
24/10/23 |
24/10/23 |
ASX - By Stock
|
25
|
12K
|
61
|
|
ASX - By Stock
|
NEU |
Phase 2
|
|
hottod
|
25 |
12K |
116 |
24/10/23 |
24/10/23 |
ASX - By Stock
|
25
|
12K
|
116
|
|
ASX - By Stock
|
NEU |
Re:
Imagine
|
|
hottod
|
9 |
5.2K |
23 |
20/10/23 |
20/10/23 |
ASX - By Stock
|
9
|
5.2K
|
23
|
|
ASX - By Stock
|
NEU |
Re:
Imagine
|
|
hottod
|
9 |
5.2K |
37 |
20/10/23 |
20/10/23 |
ASX - By Stock
|
9
|
5.2K
|
37
|
|
ASX - By Stock
|
AVE |
Re:
Ann: Phase III Clinical Trial Investor Webinar
|
|
hottod
|
92 |
28K |
2 |
19/10/23 |
19/10/23 |
ASX - By Stock
|
92
|
28K
|
2
|
|
ASX - By Stock
|
NEU |
Re:
Share Price
|
|
hottod
|
11K |
5.4M |
37 |
19/10/23 |
19/10/23 |
ASX - By Stock
|
11K
|
5.4M
|
37
|
|
ASX - By Stock
|
AVE |
Re:
Ann: Phase III Clinical Trial Investor Webinar
|
|
hottod
|
92 |
28K |
10 |
18/10/23 |
18/10/23 |
ASX - By Stock
|
92
|
28K
|
10
|
|
ASX - By Stock
|
AVE |
Re:
Ann: Phase III Clinical Trial Investor Webinar
|
|
hottod
|
92 |
28K |
17 |
13/10/23 |
13/10/23 |
ASX - By Stock
|
92
|
28K
|
17
|
|
ASX - By Stock
|
AVE |
Re:
Ann: Phase III Clinical Trial Investor Webinar
|
|
hottod
|
92 |
28K |
8 |
12/10/23 |
12/10/23 |
ASX - By Stock
|
92
|
28K
|
8
|
|
ASX - By Stock
|
PNV |
Re:
The Clinicians Speak
|
|
hottod
|
1.0K |
416K |
29 |
12/10/23 |
12/10/23 |
ASX - By Stock
|
1.0K
|
416K
|
29
|
|
ASX - By Stock
|
NEU |
Re:
Acadia
|
|
hottod
|
677 |
329K |
67 |
11/10/23 |
11/10/23 |
ASX - By Stock
|
677
|
329K
|
67
|
|
ASX - By Stock
|
NEU |
Re:
Media News
|
|
hottod
|
221 |
98K |
76 |
11/10/23 |
11/10/23 |
ASX - By Stock
|
221
|
98K
|
76
|
|
ASX - By Stock
|
NEU |
Re:
Daybue Feedback
|
|
hottod
|
47 |
23K |
33 |
07/10/23 |
07/10/23 |
ASX - By Stock
|
47
|
23K
|
33
|
|
ASX - By Stock
|
NEU |
Re:
Media News
|
|
hottod
|
221 |
98K |
43 |
06/10/23 |
06/10/23 |
ASX - By Stock
|
221
|
98K
|
43
|
|
ASX - By Stock
|
PYC |
Re:
Ann: Investor Presentation ADOA Program
|
|
hottod
|
24 |
11K |
14 |
06/10/23 |
06/10/23 |
ASX - By Stock
|
24
|
11K
|
14
|
|
ASX - By Stock
|
PYC |
Re:
Ann: Investor Presentation ADOA Program
|
|
hottod
|
24 |
11K |
12 |
05/10/23 |
05/10/23 |
ASX - By Stock
|
24
|
11K
|
12
|
|
ASX - By Stock
|
PYC |
Re:
Ann: Investor Presentation ADOA Program
|
|
hottod
|
24 |
11K |
21 |
05/10/23 |
05/10/23 |
ASX - By Stock
|
24
|
11K
|
21
|
|
ASX - By Stock
|
PYC |
Re:
Ann: PYC-001 Effective In Both NHPs and Patient-Derived Models
|
|
hottod
|
19 |
7.4K |
35 |
04/10/23 |
04/10/23 |
ASX - By Stock
|
19
|
7.4K
|
35
|
|
ASX - By Stock
|
PYC |
Re:
Ann: Q3 Investor Call Presentation
|
|
hottod
|
16 |
6.2K |
11 |
02/10/23 |
02/10/23 |
ASX - By Stock
|
16
|
6.2K
|
11
|
|
ASX - By Stock
|
PNV |
Re:
broker recommendation
|
|
hottod
|
270 |
81K |
18 |
02/10/23 |
02/10/23 |
ASX - By Stock
|
270
|
81K
|
18
|
|
ASX - By Stock
|
PNV |
Re:
Ann: BARDA increases funding US$10M
|
|
hottod
|
65 |
20K |
16 |
02/10/23 |
02/10/23 |
ASX - By Stock
|
65
|
20K
|
16
|
|
ASX - By Stock
|
PNV |
Re:
Ann: BARDA increases funding US$10M
|
|
hottod
|
65 |
20K |
38 |
02/10/23 |
02/10/23 |
ASX - By Stock
|
65
|
20K
|
38
|
|
ASX - By Stock
|
PNV |
Re:
broker recommendation
|
|
hottod
|
270 |
81K |
18 |
02/10/23 |
02/10/23 |
ASX - By Stock
|
270
|
81K
|
18
|
|
ASX - By Stock
|
PNV |
Re:
broker recommendation
|
|
hottod
|
270 |
81K |
43 |
01/10/23 |
01/10/23 |
ASX - By Stock
|
270
|
81K
|
43
|
|
ASX - By Stock
|
PYC |
Re:
Ann: Q3 Investor Call Presentation
|
|
hottod
|
16 |
6.2K |
11 |
30/09/23 |
30/09/23 |
ASX - By Stock
|
16
|
6.2K
|
11
|
|
ASX - By Stock
|
PYC |
Re:
Ann: PYC Therapeutics Investor Call - 18 August 2022
|
|
hottod
|
24 |
9.9K |
4 |
29/09/23 |
29/09/23 |
ASX - By Stock
|
24
|
9.9K
|
4
|
|
ASX - By Stock
|
PYC |
Re:
Ann: PYC Therapeutics Investor Call - 18 August 2022
|
|
hottod
|
24 |
9.9K |
10 |
29/09/23 |
29/09/23 |
ASX - By Stock
|
24
|
9.9K
|
10
|
|
ASX - By Stock
|
NEU |
Re:
Acadia
|
|
hottod
|
677 |
329K |
16 |
28/09/23 |
28/09/23 |
ASX - By Stock
|
677
|
329K
|
16
|
|
ASX - By Stock
|
NEU |
Re:
Acadia
|
|
hottod
|
677 |
329K |
4 |
28/09/23 |
28/09/23 |
ASX - By Stock
|
677
|
329K
|
4
|
|
ASX - By Stock
|
AVE |
Re:
Ann: Avecho raises further $6M for Phase III trial
|
|
hottod
|
130 |
29K |
7 |
28/09/23 |
28/09/23 |
ASX - By Stock
|
130
|
29K
|
7
|
|
ASX - By Stock
|
NEU |
Re:
Acadia
|
|
hottod
|
677 |
329K |
16 |
28/09/23 |
28/09/23 |
ASX - By Stock
|
677
|
329K
|
16
|
|